TapewireFind a company

person · Reporting owner

COHEN MARC A

Disclosed activity across 2 companies

Tapewire entity
125923
SEC CIK
0001132945

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
C4 Therapeutics, Inc.CCCC · Entity 5503DirectorJune 22, 2022June 23, 2022
Korro Bio, Inc.FREQ · Entity 6388DirectorJune 21, 2022June 23, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

C4 Therapeutics, Inc.

Report date June 22, 2022 · Filed June 23, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.06 · Expires 2032-06-21Direct23,500 Reported balance After 2022-06-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2022-06-22 · Grant · Acquired 23,500 · Balance 23,500

F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 22, 2023 and (ii) the next annual meeting of the Issuer's stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 22, 2023 and (ii) the next annual meeting of the Issuer's stockholders.

Korro Bio, Inc.

Report date June 21, 2022 · Filed June 23, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.17 · Expires 2032-06-20Direct14,846 Reported balance After 2022-06-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2022-06-21 · Grant · Acquired 14,846 · Balance 14,846

F1: The option vests in full on the earlier of June 21, 2023 or the day immediately prior to the company's 2023 annual meeting of shareholders.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in full on the earlier of June 21, 2023 or the day immediately prior to the company's 2023 annual meeting of shareholders.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 22, 2022 Filed Jun 23, 2022 16:15 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GrantStock Option (Right to Buy) · Derivative 23,500 $0.00 Strike: $6.06 $0.00
Disclosure

SEC source: 0001209191-22-038863 · doc4.xml · derivative · entry 1

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,500

Underlying: Common Stock · 23,500 shares

Expires 2032-06-21

F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 22, 2023 and (ii) the next annual meeting of the Issuer's stockholders.

Read SEC document
June 21, 2022 Filed Jun 23, 2022 16:19 UTC Korro Bio, Inc. FREQ · Entity 6388 GrantStock Option · Derivative 14,846 $0.00 Strike: $1.17 $0.00
Disclosure

SEC source: 0001127602-22-018038 · form4.xml · derivative · entry 1

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,846

Underlying: Common Stock · 14,846 shares

Expires 2032-06-20

F1 · derivative.exercise_date: The option vests in full on the earlier of June 21, 2023 or the day immediately prior to the company's 2023 annual meeting of shareholders.

Read SEC document
January 04, 2022 Filed Jan 18, 2022 16:30 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GrantCommon Stock 657 $31.58 $20,748.06
Disclosure

SEC source: 0001209191-22-003503 · doc4.xml · nonDerivative · entry 1

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,118

F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 4, 2022.

Read SEC document
October 04, 2021 Filed Oct 5, 2021 16:55 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GrantCommon Stock 461 $44.99 $20,740.39
Disclosure

SEC source: 0001209191-21-059522 · doc4.xml · nonDerivative · entry 1

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 461

F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 4, 2021.

F3 · balance_after: This amount has been adjusted to reflect 6,641 shares previously transferred from the Reporting Person to the Marc Andrew Cohen Revocable Trust.

Read SEC document
July 02, 2021 Filed Jul 7, 2021 16:30 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GrantCommon Stock 522 $39.72 $20,733.84
Disclosure

SEC source: 0001209191-21-045807 · doc4.xml · nonDerivative · entry 1

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,641

F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 2, 2021.

F3 · balance_after: This amount has been adjusted to reflect 92,817 shares previously transferred from the Reporting Person to the Marc Andrew Cohen Revocable Trust.

Read SEC document
June 17, 2021 Filed Jun 21, 2021 16:26 UTC Korro Bio, Inc. FREQ · Entity 6388 GrantStock Option · Derivative 14,846 $0.00 Strike: $10.14 $0.00
Disclosure

SEC source: 0001127602-21-020399 · form4.xml · derivative · entry 1

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,846

Underlying: Common Stock · 14,846 shares

Expires 2031-06-16

F1 · derivative.exercise_date: The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.

Read SEC document
June 15, 2021 Filed Jun 17, 2021 16:15 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GrantStock Option (Right to Buy) · Derivative 23,500 $0.00 Strike: $37.66 $0.00
Disclosure

SEC source: 0001209191-21-041423 · doc4.xml · derivative · entry 1

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,500

Underlying: Common Stock · 23,500 shares

Expires 2031-06-14

F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2022 and (ii) the next annual meeting of the Issuer's stockholders.

Read SEC document
June 14, 2021 Filed Jun 14, 2021 17:16 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 OtherCommon Stock 22,598 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-040278 · doc4.xml · nonDerivative · entry 2

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,874,805

F1 · kind: Represents the receipt of shares by the Reporting Person pursuant to pro rata distributions-in-kind, without consideration, of shares of the company's common stock effected on June 14, 2021 by Cobro Ventures Opportunity Fund, L.P. ("Cobro Ventures") to the partners of Cobro Ventures and by its general partner, Cobro Ventures Fund GP, LLC. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.nature: Shares held by Reporting Person as trustee of the Marc Andrew Cohen Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Read SEC document
June 14, 2021 Filed Jun 14, 2021 17:16 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 OtherCommon Stock 92,817 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-040278 · doc4.xml · nonDerivative · entry 1

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,936

F1 · kind: Represents the receipt of shares by the Reporting Person pursuant to pro rata distributions-in-kind, without consideration, of shares of the company's common stock effected on June 14, 2021 by Cobro Ventures Opportunity Fund, L.P. ("Cobro Ventures") to the partners of Cobro Ventures and by its general partner, Cobro Ventures Fund GP, LLC. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

Read SEC document
April 05, 2021 Filed Apr 6, 2021 16:30 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GrantCommon Stock 553 $37.51 $20,743.03
Disclosure

SEC source: 0001209191-21-025661 · doc4.xml · nonDerivative · entry 1

COHEN MARC A · CIK 0001132945 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,119

F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 5, 2021.

Read SEC document
February 18, 2021 Filed Feb 19, 2021 16:15 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 Exercise / conversionStock Option (Right to Buy) · Derivative 536 $0.00 Strike: $2.11 $0.00
Disclosure

SEC source: 0001209191-21-012339 · doc4.xml · derivative · entry 4

COHEN MARC A · CIK 0001132945 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,209

Underlying: Common Stock · 536 shares

Expires 2026-07-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Represents underlying unexercised stock options that were granted on July 13, 2016. The terms of the original grant provide that 12.5% of this option vested and became exercisable on December 31, 2016, with the remainder vesting in 28 equal quarterly installments thereafter, subject to the Reporting Person's continuous service through each such date.

Read SEC document
February 18, 2021 Filed Feb 19, 2021 16:15 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 Exercise / conversionCommon Stock 536 $2.11 $1,130.96
Disclosure

SEC source: 0001209191-21-012339 · doc4.xml · nonDerivative · entry 1

COHEN MARC A · CIK 0001132945 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,566

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 06, 2020 Filed Oct 6, 2020 21:28 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionSeries B Preferred Stock · Derivative 20,952,403 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-027697 · doc4.xml · derivative · entry 7

COHEN MARC A · CIK 0001132945 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Cobro Ventures Opportunity Fund, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 2,484,425 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F3 · ownership.nature: Shares held by Cobro Ventures Opportunity Fund, L.P. ("Cobro Ventures"). The Reporting Person serves as a manager of Cobro Opportunity Fund GP, LLC, the general partner of Cobro Ventures, and may be deemed to exercise voting and investment power over the shares held by Cobro Ventures. The Reporting Person disclaims beneficial ownership of the shares held by Cobro Ventures except to the extent of his pecuniary interest therein.

Read SEC document
October 06, 2020 Filed Oct 6, 2020 21:28 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionSeries A Preferred Stock · Derivative 12,500,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-027697 · doc4.xml · derivative · entry 6

COHEN MARC A · CIK 0001132945 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,482,183 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F2 · ownership.nature: Shares held by Reporting Person as trustee of the Marc Andrew Cohen Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Read SEC document
October 06, 2020 Filed Oct 6, 2020 21:28 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionSeries Seed Preferred Stock · Derivative 2,000,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-027697 · doc4.xml · derivative · entry 5

COHEN MARC A · CIK 0001132945 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 237,149 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F2 · ownership.nature: Shares held by Reporting Person as trustee of the Marc Andrew Cohen Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Read SEC document
October 06, 2020 Filed Oct 6, 2020 21:28 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 PurchaseCommon Stock 5,030 $19.00 $95,570.00
Disclosure

SEC source: 0000899243-20-027697 · doc4.xml · nonDerivative · entry 4

COHEN MARC A · CIK 0001132945 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,030

Read SEC document
October 06, 2020 Filed Oct 6, 2020 21:28 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionCommon Stock 2,484,425 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-027697 · doc4.xml · nonDerivative · entry 3

COHEN MARC A · CIK 0001132945 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Cobro Ventures Opportunity Fund, L.P.

Disclosed balance after: 2,484,425

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F3 · ownership.nature: Shares held by Cobro Ventures Opportunity Fund, L.P. ("Cobro Ventures"). The Reporting Person serves as a manager of Cobro Opportunity Fund GP, LLC, the general partner of Cobro Ventures, and may be deemed to exercise voting and investment power over the shares held by Cobro Ventures. The Reporting Person disclaims beneficial ownership of the shares held by Cobro Ventures except to the extent of his pecuniary interest therein.

Read SEC document
October 06, 2020 Filed Oct 6, 2020 21:28 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionCommon Stock 1,482,183 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-027697 · doc4.xml · nonDerivative · entry 2

COHEN MARC A · CIK 0001132945 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,852,207

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F2 · ownership.nature: Shares held by Reporting Person as trustee of the Marc Andrew Cohen Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Read SEC document
October 06, 2020 Filed Oct 6, 2020 21:28 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionCommon Stock 237,149 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-027697 · doc4.xml · nonDerivative · entry 1

COHEN MARC A · CIK 0001132945 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 370,024

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F2 · ownership.nature: Shares held by Reporting Person as trustee of the Marc Andrew Cohen Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 21:00 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GrantStock Option (Right to Buy) · Derivative 17,786 $0.00 Strike: $19.00 $0.00
Disclosure

SEC source: 0000899243-20-027447 · doc4.xml · derivative · entry 2

COHEN MARC A · CIK 0001132945 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,786

Underlying: Common Stock · 17,786 shares

Expires 2030-09-30

F2 · derivative.exercise_date: This option shall vest and become exercisable upon the earlier to occur of (i) October 1, 2021, and (ii) the next annual meeting of the Issuer's stockholders.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 21:00 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GrantStock Option (Right to Buy) · Derivative 725,002 $0.00 Strike: $19.00 $0.00
Disclosure

SEC source: 0000899243-20-027447 · doc4.xml · derivative · entry 1

COHEN MARC A · CIK 0001132945 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 725,002

Underlying: Common Stock · 725,002 shares

Expires 2030-09-30

F1 · derivative.exercise_date: 12.5% of this option shall vest and become exercisable on April 1, 2021, with the remainder vesting in 14 equal quarterly installments thereafter.

Read SEC document
June 11, 2020 Filed Jun 12, 2020 07:19 UTC Korro Bio, Inc. FREQ · Entity 6388 GrantStock Option · Derivative 14,846 $0.00 Strike: $18.63 $0.00
Disclosure

SEC source: 0001127602-20-019478 · form4.xml · derivative · entry 1

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,846

Underlying: Common Stock · 14,846 shares

Expires 2030-06-10

F1 · derivative.exercise_date: The option vests in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders.

Read SEC document
January 30, 2020 Filed Feb 3, 2020 16:05 UTC Korro Bio, Inc. FREQ · Entity 6388 Exercise / conversionStock Option · Derivative 20,778 $0.00 Strike: $3.37 $0.00
Disclosure

SEC source: 0000899243-20-002536 · doc4.xml · derivative · entry 11

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,778 shares

Expires 2029-04-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option is fully vested.

Read SEC document
January 30, 2020 Filed Feb 3, 2020 16:05 UTC Korro Bio, Inc. FREQ · Entity 6388 Exercise / conversionStock Option · Derivative 20,778 $0.00 Strike: $3.37 $0.00
Disclosure

SEC source: 0000899243-20-002536 · doc4.xml · derivative · entry 10

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,778 shares

Expires 2029-04-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option is fully vested.

Read SEC document
January 30, 2020 Filed Feb 3, 2020 16:05 UTC Korro Bio, Inc. FREQ · Entity 6388 Exercise / conversionStock Option · Derivative 21,827 $0.00 Strike: $3.37 $0.00
Disclosure

SEC source: 0000899243-20-002536 · doc4.xml · derivative · entry 9

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,918

Underlying: Common Stock · 21,827 shares

Expires 2029-04-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a two year period commencing on February 1, 2019, and will be fully vested and exercisable on January 1, 2021.

Read SEC document
January 30, 2020 Filed Feb 3, 2020 16:05 UTC Korro Bio, Inc. FREQ · Entity 6388 Exercise / conversionStock Option · Derivative 16,691 $0.00 Strike: $0.61 $0.00
Disclosure

SEC source: 0000899243-20-002536 · doc4.xml · derivative · entry 8

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,072

Underlying: Common Stock · 16,691 shares

Expires 2028-05-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2018, and will be fully vested and exercisable on January 1, 2022.

Read SEC document
January 30, 2020 Filed Feb 3, 2020 16:05 UTC Korro Bio, Inc. FREQ · Entity 6388 Exercise / conversionStock Option · Derivative 8,042 $0.00 Strike: $0.61 $0.00
Disclosure

SEC source: 0000899243-20-002536 · doc4.xml · derivative · entry 7

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,063

Underlying: Common Stock · 8,042 shares

Expires 2027-06-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2017, and will be fully vested and exercisable on January 1, 2021.

Read SEC document
January 30, 2020 Filed Feb 3, 2020 16:05 UTC Korro Bio, Inc. FREQ · Entity 6388 Exercise / conversionCommon Stock 20,778 $3.37 $70,021.86
Disclosure

SEC source: 0000899243-20-002536 · doc4.xml · nonDerivative · entry 5

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · The Marc Andrew Cohen Revocable Trust

Disclosed balance after: 605,820

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 30, 2020 Filed Feb 3, 2020 16:05 UTC Korro Bio, Inc. FREQ · Entity 6388 Exercise / conversionCommon Stock 20,778 $3.37 $70,021.86
Disclosure

SEC source: 0000899243-20-002536 · doc4.xml · nonDerivative · entry 4

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · The Marc Andrew Cohen Revocable Trust

Disclosed balance after: 585,042

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 30, 2020 Filed Feb 3, 2020 16:05 UTC Korro Bio, Inc. FREQ · Entity 6388 Exercise / conversionCommon Stock 21,827 $3.37 $73,556.99
Disclosure

SEC source: 0000899243-20-002536 · doc4.xml · nonDerivative · entry 3

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · The Marc Andrew Cohen Revocable Trust

Disclosed balance after: 564,264

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 30, 2020 Filed Feb 3, 2020 16:05 UTC Korro Bio, Inc. FREQ · Entity 6388 Exercise / conversionCommon Stock 16,691 $0.61 $10,181.51
Disclosure

SEC source: 0000899243-20-002536 · doc4.xml · nonDerivative · entry 2

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · The Marc Andrew Cohen Revocable Trust

Disclosed balance after: 542,437

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 30, 2020 Filed Feb 3, 2020 16:05 UTC Korro Bio, Inc. FREQ · Entity 6388 Exercise / conversionCommon Stock 8,042 $0.61 $4,905.62
Disclosure

SEC source: 0000899243-20-002536 · doc4.xml · nonDerivative · entry 1

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · The Marc Andrew Cohen Revocable Trust

Disclosed balance after: 525,746

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 03, 2019 Filed Dec 5, 2019 15:00 UTC Korro Bio, Inc. FREQ · Entity 6388 GrantStock Option · Derivative 20,778 $0.00 Strike: $3.37 $0.00
Disclosure

SEC source: 0000899243-19-028544 · doc4.xml · derivative · entry 1

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,778

Underlying: Common Stock · 20,778 shares

Expires 2029-04-16

F1 · derivative.exercise_date: The option is fully vested.

Read SEC document
October 07, 2019 Filed Oct 8, 2019 20:31 UTC Korro Bio, Inc. FREQ · Entity 6388 ConversionSeries C Preferred Stock · Derivative 163,388 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-025352 · doc4.xml · derivative · entry 5

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · The Marc Andrew Cohen Revocable Trust

Disclosed balance after: 0

Underlying: Common Stock · 24,258 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis.

F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis.

F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis.

F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis.

Read SEC document
October 07, 2019 Filed Oct 8, 2019 20:31 UTC Korro Bio, Inc. FREQ · Entity 6388 ConversionSeries B Preferred Stock · Derivative 543,219 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-025352 · doc4.xml · derivative · entry 4

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · The Marc Andrew Cohen Revocable Trust

Disclosed balance after: 0

Underlying: Common Stock · 80,650 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis.

F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis.

F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis.

F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis.

Read SEC document
October 07, 2019 Filed Oct 8, 2019 20:31 UTC Korro Bio, Inc. FREQ · Entity 6388 ConversionSeries A Preferred Stock · Derivative 2,292,235 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-025352 · doc4.xml · derivative · entry 3

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · The Marc Andrew Cohen Revocable Trust

Disclosed balance after: 0

Underlying: Common Stock · 340,321 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis.

F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis.

F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis.

F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis.

Read SEC document
October 07, 2019 Filed Oct 8, 2019 20:31 UTC Korro Bio, Inc. FREQ · Entity 6388 PurchaseCommon Stock 17,857 $14.00 $249,998.00
Disclosure

SEC source: 0000899243-19-025352 · doc4.xml · nonDerivative · entry 2

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,857

Read SEC document
October 07, 2019 Filed Oct 8, 2019 20:31 UTC Korro Bio, Inc. FREQ · Entity 6388 ConversionCommon Stock 445,229 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-025352 · doc4.xml · nonDerivative · entry 1

COHEN MARC A · CIK 0001132945 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · The Marc Andrew Cohen Revocable Trust

Disclosed balance after: 517,704

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis.

F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.